Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Open accessThe DOI matches its Crossref record; 564 of the 564 references it cites were found in a registry or an index.
Abstract
It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accurately diagnosing sepsis is challenging as sepsis can present in subtle ways, and some presentations that first appear to be sepsis turn out to be noninfectious conditions (90, 93, 107, 108).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [108]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daily chlorhexidine bathing of ICU patients decreases risk of bloodstream infections in general, including candidemia.125,164”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [125]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mainstay of treatment for most cases of uncomplicated VVC is azole antifungals, which, by inhibiting the fungal enzyme CYP51, prevent the accumulation of fungitoxic sterols [11,34].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most clinical practice guidelines, oral fluconazole is recommended as the first-line treatment.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Pappas et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Pappas et al., 2016
Experimental — accuracy not yet measured
28 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 5×
“world for more than a decade [5–12].”
BackgroundInfluentialEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“glabrata [47, 177–179].”
BackgroundMultistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“last iteration of these guidelines in 2009 [1], there have been new data pertaining to diagnosis, prevention, and treatment for proven or suspected invasive candidiasis, leading to significant modifications in our treatment recommendations.”
BackgroundSelf-citationGRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Stoll, B. J. (2004) · JAMA · doi:10.1001/jama.292.19.2357 · Cited by 1,533
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Self-citation
Research works printed but not linked: 1
- Sobel, 2002, Controversies in the diagnosis of candiduria: what is the critical colony count?, Curr Treatment Options Infect Dis, 4, 81
Cited by
Items 101–200 of 213
CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility
Krishnan, B. R., James, K. D., Polowy, K., Bryant, B. J., Vaidya, A., Smith, S., & Laudeman, C. P. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.89 · Cited by 98
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93
“Therefore, current treatment recommendations advise administration of an echinocandin to patients with known C. glabrata infections (Pappas et al., 2016).”
BackgroundStrategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries
Kaur, H., & Chakrabarti, A. (2017) · Journal of Fungi · doi:10.3390/jof3030041 · Cited by 93
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Self-citationIbrexafungerp: A novel oral glucan synthase inhibitor
Davis, M. R., Donnelley, M. A., & Thompson, G. R. (2020) · Medical Mycology · doi:10.1093/mmy/myz083 · Cited by 91
Bilal, H., Shafiq, M., Hou, B., Islam, R., Khan, M. N., Khan, R. U., & Zeng, Y. (2022) · Virulence · doi:10.1080/21505594.2022.2123325 · Cited by 91
Ben-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., Lurie-Weinberger, M., & Berman, J. (2016) · mBio · doi:10.1128/mbio.00655-16 · Cited by 88
Spec, A., Pullman, J., Thompson, G. R., Powderly, W. G., Tobin, E. H., Vazquez, J., Wring, S. A., Angulo, D., Helou, S., Pappas, P. G., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz277 · Cited by 88
Self-citationSurviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Azole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
Martens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.023 · Cited by 86
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84
Donders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82
“In the European guidelines and according to the Infectious Diseases Society of America guidelines, four or more symptomatic episodes of VVC per year are needed for this diagnosis (Pappas et al., 2015; Sherrard et al., 2018; Farr et al., 2021a; McKloud et al., 2021).”
BackgroundMethodBenedict, K., Roy, M., Kabbani, S., Anderson, E. J., Farley, M. M., Harb, S., Harrison, L. H., Bonner, L., Wadu, V. L., Marceaux, K., et al. (2018) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piy009 · Cited by 81
“The 2009 and 2016 Infectious Diseases Society of America clinical practice guidelines for the management of candidiasis recommend antifungal prophylaxis in neonates who weigh less than 1000 g and are in a neonatal ICU (NICU) with a high candidemia rate [8, 9].”
BackgroundYang, F., Zhang, L., Wakabayashi, H., Myers, J., Jiang, Y., Cao, Y., Jimenez-Ortigosa, C., Perlin, D. S., & Rustchenko, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00071-17 · Cited by 81
“toxicity and high efficacy, especially against Candida isolates resistant to azole drugs (1).”
BackgroundCD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Brand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.03.001 · Cited by 78
Self-citationOteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis
Sobel, J. D., & Nyirjesy, P. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0173 · Cited by 78
Self-citationInvasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
Fungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
Mazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac004 · Cited by 68
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68
Are the Statins promising antifungal agents against invasive candidiasis?
Lima, W. G., Alves-Nascimento, L. A., Andrade, J. T., Vieira, L., de Azambuja Ribeiro, R. I. M., Thomé, R. G., dos Santos, H. B., Ferreira, J. M. S., & Soares, A. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.076 · Cited by 65
Brüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00232-5 · Cited by 67
Rezafungin: a novel antifungal for the treatment of invasive candidiasis
Ham, Y. Y., Lewis, J. S., & Thompson, G. R. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0217 · Cited by 66
Riera, F. O., Caeiro, J. P., Angiolini, S. C., Vigezzi, C., Rodriguez, E., Icely, P. A., & Sotomayor, C. E. (2022) · Antibiotics · doi:10.3390/antibiotics11070877 · Cited by 65
Eradication of Candida albicans persister cell biofilm by the membranotropic peptide gH625
Galdiero, E., de Alteriis, E., De Natale, A., D’Alterio, A., Siciliano, A., Guida, M., Lombardi, L., Falanga, A., & Galdiero, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-62746-w · Cited by 65
Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad256 · Cited by 65
Self-citationNew antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
A common vesicle proteome drives fungal biofilm development
Zarnowski, R., Sanchez, H., Jaromin, A., Zarnowska, U. J., Nett, J. E., Mitchell, A. P., & Andes, D. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211424119 · Cited by 63
Self-citationIn vitro Antifungal Effects of Berberine Against Candida spp. In Planktonic and Biofilm Conditions
Xie, Y., Liu, X., & Zhou, P. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s230857 · Cited by 63
Yang, F., Scopel, E. F. C., Li, H., Sun, L.-L., Kawar, N., Cao, Y.-B., Jiang, Y.-Y., & Berman, J. (2023) · mBio · doi:10.1128/mbio.00227-23 · Cited by 62
“Echinocandins are fungicidal against most Candida species and are first-line drugs for the treatment of candidemia (5).”
BackgroundTurbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle-mediated trafficking
Zhao, M., Zhang, F., Zarnowski, R., Barns, K., Jones, R., Fossen, J., Sanchez, H., Rajski, S. R., Audhya, A., Bugni, T. S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145123 · Cited by 62
Self-citationReemergence of intravenous drug use as risk factor for candidemia, Massachusetts, USA.
Poowanawittayakom, N., Dutta, A., Stock, S., Touray, S., Ellison, R. T., & Levitz, S. M. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171807 · Cited by 58
“However, it seems reasonable to begin to treat patients with an echinocandin, according to the Infectious Diseases Society of America clinical practice guideline for the treatment of candidemia (19), pending identification and susceptibility testing of the isolate.”
BackgroundA Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61
Lockhart, S. R., Jackson, B. R., Vallabhaneni, S., Ostrosky-Zeichner, L., Pappas, P. G., & Chiller, T. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01355-17 · Cited by 61
“The Infectious Disease Society of America (IDSA) treatment guidelines on management of invasive candidiasis recommend that antifungal susceptibility testing be performed on all Candida isolates from sterile body sites (6).”
BackgroundSelf-citationBaldesi, O., Bailly, S., Ruckly, S., Lepape, A., L'Heriteau, F., Aupee, M., Boussat, S., Bervas, C., Machut, A., Berger-Carbonne, A., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.03.011 · Cited by 60
Gold, J. A. W., Ahmad, F. B., Cisewski, J. A., Rossen, L. M., Montero, A. J., Benedict, K., Jackson, B. R., & Toda, M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac489 · Cited by 60
Tunicamycin Potentiates Antifungal Drug Tolerance via Aneuploidy in Candida albicans
Yang, F., Gritsenko, V., Slor Futterman, Y., Gao, L., Zhen, C., Lu, H., Jiang, Y.-Y., & Berman, J. (2021) · mBio · doi:10.1128/mbio.02272-21 · Cited by 59
Arastehfar, A., Daneshnia, F., Cabrera, N., Penalva-Lopez, S., Sarathy, J., Zimmerman, M., Shor, E., & Perlin, D. S. (2023) · Nature Communications · doi:10.1038/s41467-023-36882-6 · Cited by 58
Johnson, C. J., Kernien, J. F., Hoyer, A. R., & Nett, J. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-13588-6 · Cited by 58
International Multicentre Study of Candida auris Infections
Pandya, N., Cag, Y., Pandak, N., Pekok, A. U., Poojary, A., Ayoade, F., Fasciana, T., Giammanco, A., Caskurlu, H., Rajani, D. P., et al. (2021) · Journal of Fungi · doi:10.3390/jof7100878 · Cited by 56
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
Neal, C. M., & Martens, M. G. (2022) · SAGE Open Medicine · doi:10.1177/20503121221115201 · Cited by 56
Race and ethnicity: Risk factors for fungal infections?
Jenks, J. D., Aneke, C. I., Al-Obaidi, M. M., Egger, M., Garcia, L., Gaines, T., Hoenigl, M., & Thompson, G. R. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011025 · Cited by 55
Fungal infections in immunocompromised critically ill patients
Garnacho-Montero, J., Barrero-García, I., & León-Moya, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.01.005 · Cited by 56
Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs
Eldesouky, H. E., Mayhoub, A., Hazbun, T. R., & Seleem, M. N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-17 · Cited by 55
Asadzadeh, M., Mokaddas, E., Ahmad, S., Abdullah, A. A., de Groot, T., Meis, J. F., & Shetty, S. A. (2022) · Mycoses · doi:10.1111/myc.13419 · Cited by 55
Antifungal Drug Concentration Impacts the Spectrum of Adaptive Mutations in Candida albicans
Todd, R. T., Soisangwan, N., Peters, S., Kemp, B., Crooks, T., Gerstein, A., & Selmecki, A. (2023) · Molecular Biology and Evolution · doi:10.1093/molbev/msad009 · Cited by 53
“Lower doses of FLC are used as prophylaxis for patients undergoing solid tissue transplantation (Felton et al. 2014; Pappas et al. 2016; Schiave et al. 2018) and recurrent vulvovaginal candidiasis (Denning et al.”
Fan, X., Dai, R.-C., Zhang, S., Geng, Y.-Y., Kang, M., Guo, D.-W., Mei, Y.-N., Pan, Y.-H., Sun, Z.-Y., Xu, Y.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43380-2 · Cited by 55
Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R. (2022) · NEJM Evidence · doi:10.1056/evidoa2100055 · Cited by 55
Self-citationHodges, M. R., Ople, E., Wedel, P., Shaw, K. J., Jakate, A., Kramer, W. G., Marle, S. V., van Hoogdalem, E.-J., & Tawadrous, M. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-22 · Cited by 52
Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression
Wang, D., An, N., Yang, Y., Yang, X., Fan, Y., & Feng, J. (2021) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-021-00890-2 · Cited by 52
Holbrook, S. Y. L., Garzan, A., Dennis, E. K., Shrestha, S. K., & Garneau-Tsodikova, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.030 · Cited by 51
Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Kuster, S., Stampf, S., Gerber, B., Baettig, V., Weisser, M., Gerull, S., Medinger, M., Passweg, J., Schanz, U., Garzoni, C., et al. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12981 · Cited by 48
Treatment for recurrent vulvovaginal candidiasis (thrush)
Cooke, G., Watson, C., Deckx, L., Pirotta, M., Smith, J., & van Driel, M. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009151.pub2 · Cited by 48
Chiotos, K., Vendetti, N., Zaoutis, T. E., Baddley, J., Ostrosky-Zeichner, L., Pappas, P., & Fisher, B. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw305 · Cited by 48
Self-citationContinual decline in azole susceptibility rates in candida tropicalis over a 9-year period in China
Wang, Y., Fan, X., Wang, H., Kudinha, T., Mei, Y.-N., Ni, F., Pan, Y.-H., Gao, L.-M., Xu, H., Kong, H.-S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.702839 · Cited by 47
Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis
Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46
Self-citationTrends in antifungal use in US hospitals, 2006–12
Vallabhaneni, S., Baggs, J., Tsay, S., Srinivasan, A. R., Jernigan, J. A., & Jackson, B. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky270 · Cited by 45
Desnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-20 · Cited by 44
Marcos-Zambrano, L. J., Gómez-Perosanz, M., Escribano, P., Bouza, E., & Guinea, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx010 · Cited by 44
The Role of Fatty Acid Metabolites in Vaginal Health and Disease: Application to Candidiasis
Baldewijns, S., Sillen, M., Palmans, I., Vandecruys, P., Van Dijck, P., & Demuyser, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.705779 · Cited by 44
“The current treatment recommendations of uncomplicated VVC by the American Centers for Disease Control and Prevention (CDC) are topical formulations or a single oral dose of fluconazole (Pappas et al., 2016).”
Hou, X., Healey, K. R., Shor, E., Kordalewska, M., Ortigosa, C. J., Paderu, P., Xiao, M., Wang, H., Zhao, Y., Lin, L.-Y., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1684209 · Cited by 43
Jenkins, E. N., Gold, J. A. W., Benedict, K., Lockhart, S. R., Berkow, E. L., Dixon, T., Shack, S. L., Witt, L. S., Harrison, L. H., Seopaul, S., et al. (2025) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7404a1 · Cited by 43
“Candidiasis is a fungal infection caused by yeast from the genus Candida ( 1 ).”
Papp, C., Bohner, F., Kocsis, K., Varga, M., Szekeres, A., Bodai, L., Willis, J. R., Gabaldón, T., Tóth, R., Nosanchuk, J. D., et al. (2020) · mSphere · doi:10.1128/msphere.00821-20 · Cited by 42
“highest in vitro MIC values for echinocandins compared to other Candida species (7).”
BackgroundBassetti, M., Vena, A., Bouza, E., Peghin, M., Muñoz, P., Righi, E., Pea, F., Lackner, M., & Lass-Flörl, C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.02.017 · Cited by 40
Al-Obaid, I., Asadzadeh, M., Ahmad, S., Alobaid, K., Alfouzan, W., Bafna, R., Emara, M., & Joseph, L. (2022) · Journal of Fungi · doi:10.3390/jof8030267 · Cited by 39
The assimilation of different carbon sources in Candida albicans: Fitness and pathogenicity
Lok, B., Adam, M. A. A., Kamal, L. Z. M., Chukwudi, N. A., Sandai, R., & Sandai, D. (2021) · Medical Mycology · doi:10.1093/mmy/myaa080 · Cited by 39
Micafungin breakthrough fungemia in patients with hematological disorders
Kimura, M., Araoka, H., Yamamoto, H., Nakamura, S., Nagi, M., Yamagoe, S., Miyazaki, Y., Ogura, S., Mitsuki, T., Yuasa, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02183-17 · Cited by 37
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Kukurudz, R. J., Chapel, M., Wonitowy, Q., Adamu Bukari, A.-R., Sidney, B., Sierhuis, R., & Gerstein, A. C. (2022) · G3 · doi:10.1093/g3journal/jkac156 · Cited by 35
Jenull, S., Shivarathri, R., Tsymala, I., Penninger, P., Trinh, P.-C., Nogueira, F., Chauhan, M., Singh, A., Petryshyn, A., Stoiber, A., et al. (2022) · mBio · doi:10.1128/mbio.00799-22 · Cited by 32
“As ECN stands out as the recommended first-line therapy against invasive candidiasis (72), an increase in ECN resistance among Candida spp.”
BackgroundScope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates
Marcos-Zambrano, L. J., Escribano, P., Sánchez-Carrillo, C., Bouza, E., & Guinea, J. (2016) · Medical Mycology · doi:10.1093/mmy/myw033 · Cited by 33
Ramos, R., Caceres, D. H., Perez, M., Garcia, N., Castillo, W., Santiago, E., Borace, J., Lockhart, S. R., Berkow, E. L., Hayer, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00371-18 · Cited by 32
Chen, X.-C., Xu, J., & Wu, D.-P. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1523 · Cited by 32
Cruz, M. R., Cristy, S., Guha, S., De Cesare, G. B., Evdokimova, E., Sanchez, H., Borek, D., Miramón, P., Yano, J., Fidel, P. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33613-1 · Cited by 30
Self-citationBiofilms and beyond: Expanding echinocandin utility
Larkin, E. L., Dharmaiah, S., & Ghannoum, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx451 · Cited by 31
Lu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
Esfahani, A., Omran, A. N., Salehi, Z., Shams-Ghahfarokhi, M., Ghane, M., Eybpoosh, S., & Razzaghi-Abyaneh, M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105696 · Cited by 30
Baker, K. M., Hoda, S., Saha, D., Gregor, J. B., Georgescu, L., Serratore, N. D., Zhang, Y., Cheng, L., Lanman, N. A., & Briggs, S. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02250-21 · Cited by 30
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03158-4 · Cited by 26
Phan, Q. T., Solis, N. V., Cravener, M. V., Swidergall, M., Lin, J., Huang, M. Y., Liu, H., Singh, S., Ibrahim, A. S., Mazzone, M., et al. (2023) · PLOS Pathogens · doi:10.1371/journal.ppat.1011579 · Cited by 29
Crouss, T., Sobel, J. D., Smith, K., & Nyirjesy, P. (2018) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000413 · Cited by 29
Self-citationMSH2 Gene Point Mutations Are Not Antifungal Resistance Markers in Candida glabrata
Bordallo-Cardona, M. Á., Agnelli, C., Gómez-Nuñez, A., Sánchez-Carrillo, C., Bouza, E., Muñoz, P., Escribano, P., & Guinea, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01876-18 · Cited by 27
Endogenous Candida endophthalmitis: Who is really at risk?
Seidelman, J., Fleece, M., Bloom, A., Lydon, E., Yang, W., Arnold, C., Weber, D. J., & Okeke, N. L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2020.12.032 · Cited by 26
Robbins, N., & Cowen, L. E. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.071 · Cited by 24
Kim, S.-H., Choi, J.-K., Cho, S.-Y., Lee, H.-J., Park, S. H., Choi, S.-M., Lee, D.-G., Choi, J.-H., Yoo, J.-H., & Lee, J.-W. (2018) · Medical Mycology · doi:10.1093/mmy/myx038 · Cited by 24
“Hematopoietic stem cell transplantation 6 (12) 3 (14) 3 (11) Supportive therapy 14 (29) 4 (19) 10 (36)”
Unveiling the menace: a thorough review of potential pandemic fungal disease
Jafarlou, M. (2024) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2024.1338726 · Cited by 24
Approaches for identifying and measuring heteroresistance in azole-susceptible Candida isolates
Gautier, C., Maciel, E. I., & Ene, I. V. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04041-23 · Cited by 23
Healey, K. R., Paderu, P., Hou, X., Jimenez Ortigosa, C., Bagley, N., Patel, B., Zhao, Y., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030143 · Cited by 23
van Riel, S. J. J. M., Lardenoije, C. M. J. G., Oudhuis, G. J., & Cremers, N. A. J. (2021) · Journal of Fungi · doi:10.3390/jof7080664 · Cited by 22
McCarty, T. P., Lockhart, S. R., Moser, S. A., Whiddon, J., Zurko, J., Pham, C. D., & Pappas, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky059 · Cited by 21
Self-citationKan, S., Song, N., Pang, Q., Mei, H., Zheng, H., Li, D., Cui, F., Lv, G., An, R., Li, P., et al. (2023) · Mycopathologia · doi:10.1007/s11046-022-00687-w · Cited by 21
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
Metadata
- Authors
- Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D.
- Affiliations
- University of Alabama at Birmingham (US)
- University of Michigan (US)
- University of Wisconsin–Madison (US)
- University of Pittsburgh (US)
- Johns Hopkins University (US)
- University of Texas Health Science Center, Houston
- Cooper Medical School of Rowan University (US)
- University of Pennsylvania (US)
- Georgia Regents University, Augusta
- Cornell University (US)
- Children's Hospital of Pennsylvania, Philadelphia
- Wayne State University (US)
- Corresponding author
- Pappas, Peter G.
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-16
- Volume
- 62
- Issue
- 4
- Pages
- e1-e50
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4725385
- OpenAlex
- W2216117396
- Semantic Scholar
- 32a81df25cfe286355f8b42bb1a020d93fa4673f
- Cited by
- 4,200
- References
- 564
- Citations by year
- 2026: 477 · 2025: 520 · 2024: 424 · 2023: 464 · 2022: 422 · 2021: 456 · 2020: 388 · 2019: 322 · 2018: 332 · 2017: 261 · 2016: 124 · 2015: 1
- FWCI
- 185.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- the Infectious Diseases Society of America
- National Institutes of Health
- NIH
- National Institute of Dental and Craniofacial Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidiasis, antifungal therapy, fungal infection, clinical management, treatment guidelines
- MeSH terms
- Animals, Antifungal Agents, Candidiasis, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.